Subtopic Deep Dive
Granulocyte Colony-Stimulating Factor in Neutropenia
Research Guide
What is Granulocyte Colony-Stimulating Factor in Neutropenia?
Granulocyte colony-stimulating factor (G-CSF), including filgrastim and pegfilgrastim, stimulates neutrophil production to shorten neutropenia duration and reduce infection risk in cancer patients undergoing chemotherapy.
G-CSF enables dose-dense chemotherapy by mitigating neutropenia-related complications in solid tumors and hematologic malignancies. Meta-analyses confirm prophylactic G-CSF reduces febrile neutropenia incidence by 50% (Kuderer et al., 2007, 713 citations). Guidelines from ASCO and EORTC recommend its use based on chemotherapy risk models (Smith et al., 2006, 1639 citations; Aapro et al., 2010, 1060 citations).
Why It Matters
G-CSF prophylaxis cuts febrile neutropenia rates, enabling intensified regimens that improve survival in lymphoma and breast cancer (Kuderer et al., 2007). Bodey et al. (1966, 2475 citations) established infection risk thresholds below 100 neutrophils/μL, guiding G-CSF dosing. ASCO updates (Smith et al., 2015, 876 citations) integrate risk models for prophylactic use, reducing hospitalizations by 40-50%. In leukemia, G-CSF supports transplantation protocols (Tomblyn et al., 2009, 1727 citations).
Key Research Challenges
Optimal Prophylactic Timing
Guidelines differ on primary vs secondary prophylaxis timing to balance neutropenia duration and infection rates (Smith et al., 2006). Crawford et al. (2004, 855 citations) highlight variable chemotherapy regimens complicating universal thresholds. Meta-analyses show mortality benefits but need patient-specific models (Kuderer et al., 2007).
Cost-Effectiveness Assessment
High G-CSF costs versus infection reduction benefits require economic modeling across tumor types (Lyman et al. in Smith et al., 2015). Trials show FN risk reduction but variable QALY gains (Aapro et al., 2010). Real-world data gaps persist for dose-dense schedules.
Resistance and Long-term Effects
Potential G-CSF induced neutrophil dysfunction raises concerns in prolonged use (Bodey et al., 1966). Guidelines note limited data on leukemia progression risks (Hughes et al., 2002, 1970 citations). Balancing short-term gains against myeloid malignancy risks remains unresolved.
Essential Papers
Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia
Gerald P. Bodey, MONICA BUCKLEY, Y. S. SATHE et al. · 1966 · Annals of Internal Medicine · 2.5K citations
Article1 February 1966Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute LeukemiaGERALD P. BODEY, M.D., MONICA BUCKLEY, B.A., Y. S. SATHE, PH.D., EMIL J ...
2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer
Walter T. Hughes, Donald Armstrong, Gerald P. Bodey et al. · 2002 · Clinical Infectious Diseases · 2.0K citations
This article, prepared by the Infectious Diseases Society of America (IDSA) Fever and Neutropenia Guidelines Panel, updates guidelines established a decade ago by the Infectious Disease Society of ...
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
Marcie Tomblyn, Tom Chiller, Hermann Einsele et al. · 2009 · Biology of Blood and Marrow Transplantation · 1.7K citations
2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline
Thomas J. Smith, James Khatcheressian, Gary H. Lyman et al. · 2006 · Journal of Clinical Oncology · 1.6K citations
Purpose To update the 2000 American Society of Clinical Oncology guideline on the use of hematopoietic colony-stimulating factors (CSF). Update Methodology The Update Committee completed a review a...
Guidelines for Treatment of Candidiasis
Peter G. Pappas, John Rex, Jack D. Sobel et al. · 2004 · Clinical Infectious Diseases · 1.4K citations
Good evidence to support a recommendation against use Quality of evidence 1 Evidence from у1 properly randomized, controlled trial 2 Evidence from у1 well-designed clinical trial, without randomiza...
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
Matti Aapro, Julia Bohlius, David Cameron et al. · 2010 · European Journal of Cancer · 1.1K citations
Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update
Thomas J. Smith, Kari Bohlke, Gary H. Lyman et al. · 2015 · Journal of Clinical Oncology · 876 citations
Purpose To update the 2006 American Society of Clinical Oncology guideline on the use of hematopoietic colony-stimulating factors (CSFs). Methods The American Society of Clinical Oncology convened ...
Reading Guide
Foundational Papers
Start with Bodey et al. (1966, 2475 citations) for leukocyte-infection relationships establishing neutropenia risk; Smith et al. (2006, 1639 citations) for initial ASCO G-CSF recommendations; Hughes et al. (2002, 1970 citations) for neutropenic infection management context.
Recent Advances
Study Smith et al. (2015, 876 citations) for updated ASCO guidelines integrating new trials; Aapro et al. (2010, 1060 citations) for EORTC FN prophylaxis in solid tumors.
Core Methods
Risk-adapted prophylaxis via MASCC index; meta-regression of RCTs for FN/mortality (Kuderer et al., 2007); ANC monitoring with thresholds from Bodey curves.
How PapersFlow Helps You Research Granulocyte Colony-Stimulating Factor in Neutropenia
Discover & Search
Research Agent uses searchPapers for 'G-CSF filgrastim neutropenia meta-analysis' retrieving Kuderer et al. (2007), then citationGraph reveals 700+ citing works including Smith et al. (2015), and findSimilarPapers expands to EORTC guidelines (Aapro et al., 2010). exaSearch uncovers guideline updates across ASCO/IDSA.
Analyze & Verify
Analysis Agent applies readPaperContent to extract FN risk reductions from Kuderer et al. (2007), verifyResponse with CoVe cross-checks claims against Bodey et al. (1966), and runPythonAnalysis computes infection probabilities from leukocyte data via NumPy/pandas. GRADE grading scores evidence as high for prophylaxis (Smith et al., 2006).
Synthesize & Write
Synthesis Agent detects gaps in cost-effectiveness models across solid tumors, flags contradictions between ASCO (Smith et al., 2015) and EORTC (Aapro et al., 2010) thresholds. Writing Agent uses latexEditText for guideline summaries, latexSyncCitations for 10+ papers, latexCompile for reports, and exportMermaid for FN risk flowcharts.
Use Cases
"Analyze G-CSF impact on FN mortality from RCTs"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (meta-analysis forest plot with pandas/matplotlib) → outputs RR=0.64 (95% CI) from Kuderer et al. (2007).
"Draft LaTeX review on ASCO G-CSF guidelines"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Smith 2006/2015) + latexCompile → researcher gets formatted PDF with citations.
"Find code for neutropenia risk calculators"
Research Agent → paperExtractUrls (Crawford 2004) → Code Discovery → paperFindGithubRepo → githubRepoInspect → outputs Python neutropenia model repo with MASCC calculator.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers (G-CSF neutropenia, 50+ papers) → citationGraph → DeepScan (7-step GRADE analysis) → structured report on prophylactic efficacy (Kuderer et al., 2007). Theorizer generates hypotheses on G-CSF timing from Bodey (1966) leukocyte curves via runPythonAnalysis. DeepScan verifies guideline contradictions across IDSA/ASCO with CoVe checkpoints.
Frequently Asked Questions
What defines G-CSF use in neutropenia?
G-CSF (filgrastim/pegfilgrastim) is given prophylactically to cancer patients with >20% FN risk from chemotherapy, per ASCO (Smith et al., 2015). It shortens neutropenia by 2-3 days (Kuderer et al., 2007).
What are key methods for evaluation?
Randomized trials and meta-analyses assess FN incidence and mortality (Kuderer et al., 2007). Guidelines use MASCC risk index for prophylaxis decisions (Aapro et al., 2010). Leukocyte-infection correlations from Bodey et al. (1966) inform thresholds.
What are seminal papers?
Bodey et al. (1966, 2475 citations) links low ANC to infections; Smith et al. (2006, 1639 citations) updates ASCO CSF guidelines; Kuderer et al. (2007, 713 citations) meta-analyzes G-CSF prophylaxis.
What open problems exist?
Optimal dosing in dose-dense regimens and long-term safety in AML remain unresolved (Crawford et al., 2004). Cost-effectiveness varies by healthcare system; personalized risk models needed beyond current guidelines.
Research Neutropenia and Cancer Infections with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Granulocyte Colony-Stimulating Factor in Neutropenia with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Neutropenia and Cancer Infections Research Guide